Frequency Therapeutics, Inc.
Frequency Therapeutics, Inc. is listed today as Korro Bio, Inc.: market value, financials and filings are on its company page.
Funding rounds
2 counted as startup funding, 1 other private sales on record. Open the number of investors for the round's details.
| Month | Raised | Raise | Size | Investors | Sold | Filing |
|---|---|---|---|---|---|---|
| Jul 2020 | $42 M | Private placement after listing | $10 to $50 million | equity | SEC | |
| Jul 2019 | $62 M | No. 2 | $50 to $250 million | equity | SEC | |
| Mar 2017 | $32 M | No. 1 | $10 to $50 million | equity | SEC |
Source: SEC Form D. Each row is one private sale of securities with the running total of its newest notice. The form does not name the series or the investors; rounds are numbered in the order they were filed. A round's details show what its notice does say: accredited and other investors, the smallest investment taken, the exemption claimed, fees, the people named and the brokers paid to sell it.
How it makes money#
What its filings and its own website say, sentence by sentence, each with its source.
Frequency Therapeutics, Inc. chose not to state its revenue in its newest notice of a funding round (Jul 2020).
SEC Form D · Jul 2020
The industry group it chose in its notices: Biotechnology.
SEC Form D · Jul 2020
That is all the official record says: Frequency Therapeutics, Inc. has not published its revenue in a filing we can read, and no other official source covers it. Revenue figures come from crowdfunding filings (SEC Form C) and from annual reports once a company is listed.
Products and services#
No products or services of Frequency Therapeutics, Inc. are on record.
Investors#
10 named in official filings. Open an investor to see everything it has backed.
| Investor | Kind | Amount | Round | Role | Source |
|---|---|---|---|---|---|
| Alexandria Venture Investments, LLC | Venture capital | not stated | not stated | Held Series A and B preferred stock, 10% owner (Form 3, 2019) | SEC Form 3 |
| Christopher R. Loose | Person | not stated | not stated | Held Series A preferred stock (Form 3, 2019) | SEC Form 3 |
| David L. Lucchino | Person | not stated | not stated | Held Series A and B preferred stock, director (Form 3, 2019) | SEC Form 3 |
| Deerfield Management Company, L.P. | Fund or asset manager | not stated | not stated | Held Series C preferred stock, 10% owner (Form 3, 2019) | SEC Form 3 |
| Deerfield Mgmt IV, L.P. | Fund or asset manager | not stated | not stated | Held Series C preferred stock, 10% owner (Form 3, 2019) | SEC Form 3 |
| Deerfield Mgmt L.P. | Fund or asset manager | not stated | not stated | Held Series C preferred stock, 10% owner (Form 3, 2019) | SEC Form 3 |
| Deerfield Private Design Fund IV, L.P. | Fund or asset manager | not stated | not stated | Held Series C preferred stock, 10% owner (Form 3, 2019) | SEC Form 3 |
| Deerfield Special Situations Fund, L.P. | Fund or asset manager | not stated | not stated | Held Series C preferred stock, 10% owner (Form 3, 2019) | SEC Form 3 |
| Joel S. Marcus | Person | not stated | not stated | Held Series A and B preferred stock, 10% owner, director (Form 3, 2019) | SEC Form 3 |
| Timothy J. Barberich | Person | not stated | not stated | Held Series A and C preferred stock, director (Form 3, 2019) | SEC Form 3 |
Source: SEC Form 3 statements, SEC Form N-PORT fund reports, Wikidata, value.today research. Names come from filings that do name holders: the preferred stock each holder had when the company registered its shares (Form 3), private shares in US mutual funds' portfolio reports (N-PORT), and Wikidata. None ties a name to one funding round, so this list is per company, and it is not complete: the 2 rounds above had up to 90 investors.
Largest shareholders today
Institutions holding Korro Bio, Inc. shares, as of Sep 30, 2026.
- Lynx1 Capital Management LP$15 M11.26%
- NEA Management Company, LLC$13 M9.46%
- Adage Capital Partners GP, L.L.C.$10 M7.29%
- Balyasny Asset Management L.P.$9 M6.33%
- BlackRock, Inc.$8 M6.15%
- Atlas Venture Life Science Advisors, LLC$8 M5.63%
- Nantahala Capital Management, LLC$7 M4.96%
- ADAR1 Capital Management, LLC$5 M3.93%
- Affinity Asset Advisors, LLC$5 M3.88%
- Vanguard Capital Management LLC$5 M3.48%
- Kalehua Capital Management LLC$5 M3.45%
- Driehaus Capital Management LLC$4 M3.28%
- Venrock Adviser, LLC$4 M3.23%
- TCG Crossover Management, LLC$4 M3.03%
- Siren, L.L.C.$3 M2.53%
Source: SEC Form 13F holdings reports · as of Sep 30, 2026. Value held and share of the company. All holders are on the company page.
Executives and directors
As the company named them in its notices. Directors of a funded startup are often partners of its investors.
| Name | Role | Named in |
|---|---|---|
| Carl P. LeBel | Executive officer | Jul 2020 |
| Christopher R. Loose | Executive officer | Jul 2020 |
| Dana P. Hilt | Executive officer | Jul 2020 |
| David L. Lucchino | Executive officer | Jul 2020 |
| Richard S. Mitrano | Executive officer | Jul 2020 |
| Wendy S. Arnold | Executive officer | Jul 2020 |
| Carl S. Lebel | Executive officer | Jul 2019 |
| David Lucchino | Executive officer | Jul 2019 |
| David L. Lucchino | Director | Jul 2020 |
| Joel S. Marcus | Director | Jul 2020 |
| Marc A. Cohen | Director | Jul 2020 |
| Michael S. Huang | Director | Jul 2020 |
| Robert S. Langer | Director | Jul 2020 |
| Timothy J. Barberich | Director | Jul 2020 |
| David Lucchino | Director | Jul 2019 |
| Joel R. Marcus | Director | Jul 2019 |
| Marc R. Cohen | Director | Jul 2019 |
| Timothy R. Barberich | Director | Jul 2019 |
| Marc R. Kozin | Director | Apr 2017 |
| Robert R. Langer | Director | Apr 2017 |
Went public since 2019. Its SEC number is that of a company listed on a stock exchange.